hand2 Antibody

What is HAND2 and why is it important in developmental research?

HAND2 is a basic helix-loop-helix (bHLH) transcription factor essential for multiple developmental processes. It plays crucial roles in cardiac morphogenesis, controlling atrioventricular canal development through specific target gene regulatory networks . Additionally, HAND2 is vital for the proliferation and noradrenergic differentiation of sympathetic neuron precursors and in maintaining the noradrenergic phenotype in differentiated sympathetic neurons . Recent research has also identified HAND2 as a novel obesity-linked adipogenic transcription factor . These diverse functions make HAND2 a significant target for developmental, neurobiological, and metabolic research.

What species reactivity should I consider when selecting a HAND2 antibody?

When selecting a HAND2 antibody, consider that commercially available antibodies show varying cross-reactivity patterns. For example, R&D Systems' Human/Mouse HAND2 Antibody (AF3876) specifically detects HAND2 in human and mouse samples . Other antibodies, like those from MyBioSource.com, offer broader reactivity across human, mouse, and rat specimens . For specialized research, Aviva Systems Biology provides antibodies with extended cross-reactivity to rabbit, bovine, dog, guinea pig, hamster, and zebrafish . Verify the specific reactivity profile for your target species before selection, particularly for comparative evolutionary studies.

What are the most common applications for HAND2 antibodies?

HAND2 antibodies are primarily used in Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC). The most extensively validated applications according to supplier data include:

Additionally, some antibodies have been validated for chromatin immunoprecipitation sequencing (ChIP-Seq) experiments, as evidenced by studies using anti-FLAG antibodies with HAND2-3xFLAG tagged proteins .

How should I optimize antibody dilutions for different HAND2 detection methods?

Optimal antibody dilutions vary significantly by application and specific antibody formulation. For R&D Systems' Human/Mouse HAND2 Antibody (AF3876), recommended dilutions are 0.1 μg/mL for Western blotting and 5-15 μg/mL for immunohistochemistry . For immunofluorescence applications, Abcam's Anti-HAND2 antibody [EPR19451] has been successfully used at 1/100 dilution .

Generally, follow this optimization approach:

• Begin with the manufacturer's recommended dilution

• Perform a dilution series (typically 3-5 dilutions spanning 2-fold concentrations above and below the recommended dilution)

• Include appropriate positive and negative controls

• Evaluate signal-to-noise ratio to determine optimal concentration

• Validate with tissue-specific expression patterns known for HAND2

For chromatin immunoprecipitation experiments, significantly higher antibody concentrations may be required, as seen in studies using 300 hearts per biological replicate to obtain sufficient chromatin for ChIP-Seq .

What are the appropriate controls for validating HAND2 antibody specificity?

Proper experimental controls are essential for confirming HAND2 antibody specificity:

• Positive tissue controls: Use tissues with known HAND2 expression:

  • Developing heart tissue (particularly atrioventricular canal)

  • Sympathetic ganglia

  • Embryonic neural crest derivatives

  • Mouse E14.5 embryonic adrenal gland tissue

  • Developing tongue tissues

• Negative controls:

  • Secondary antibody-only controls (omitting primary antibody)

  • Isotype controls (e.g., rabbit monoclonal IgG as demonstrated in immunoprecipitation experiments)

  • Tissues from HAND2 knockout models, such as conditional Hand2-null mice

• Molecular weight verification: Confirm band size in Western blots (predicted: 24 kDa; typically observed: 26 kDa)

• siRNA knockdown: Validate antibody specificity through siRNA-mediated HAND2 knockdown experiments, as demonstrated in chick sympathetic neuron studies

How do I design experiments to investigate HAND2 function through DNA binding-dependent and -independent mechanisms?

HAND2 functions through both DNA binding-dependent and -independent mechanisms, requiring careful experimental design:

• DNA binding-defective mutants: Studies have utilized a Hand2EDE mutant where three asparagine residues (RRR) in the basic domain are replaced with acidic residues (Glu-Asp-Glu), abolishing DNA-binding activity while maintaining protein expression, dimerization with E12, and nuclear localization .

• Chromatin immunoprecipitation approaches:

  • For genome-wide binding studies, use epitope-tagged HAND2 (e.g., Hand2 3xF allele with 3xFLAG tag)

  • Anti-FLAG antibodies can be used for immunoprecipitation followed by sequencing (ChIP-Seq)

  • Analysis of ~300 hearts per biological replicate may be necessary for sufficient chromatin

• Gene expression analysis:

  • Compare differential gene expression between wild-type and Hand2-deficient tissues

  • Identify HAND2 transcriptional targets by correlating with genes harboring HAND2 ChIP-Seq peaks in their Topologically Associating Domains (TADs)

• Rescue experiments: Perform rescue experiments with wild-type HAND2 and DNA binding-defective HAND2 to distinguish between binding-dependent and -independent functions

What are the optimal tissue preparation methods for HAND2 immunostaining in cardiac and neural tissues?

Effective tissue preparation for HAND2 detection requires specific protocols:

For paraffin-embedded tissues:

• Fix embryonic tissues appropriately (4% paraformaldehyde is commonly used)

• Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before immunostaining

• Use appropriate antibody concentrations (e.g., Anti-HAND2 antibody [EPR19451] at 1/1000 dilution)

• For visualization, use compatible secondary antibodies (e.g., Goat Anti-Rabbit IgG H&L (HRP) for rabbit primary antibodies)

• Counterstain with hematoxylin to visualize tissue architecture

For immunofluorescence:

• Fix cells with 4% paraformaldehyde

• Permeabilize with 0.1% Triton X-100

• For neuronal cell lines (e.g., Neuro-2a), Anti-HAND2 antibody has been successfully used at 1/100 dilution

For embryonic tissues:

• For mouse embryos, immersion-fixed paraffin-embedded sections from specific developmental stages (e.g., 13 d.p.c.) show optimal HAND2 detection

• Nuclear localization of HAND2 is typically observed in tissues like developing tongue, embryonic ganglia, and adrenal gland

How do HAND2 expression patterns differ across tissue types and developmental stages?

HAND2 displays distinct expression patterns across tissues and developmental timepoints:

Embryonic expression:

• Strong nuclear expression in mouse E14.5 embryonic adrenal gland tissue

• Nuclear staining in multiple rat E14.5 embryonic tissues, including gut

• Specific staining in cell nuclei of developing tongue in mouse embryos

Adipose tissue-specific patterns:

• Higher HAND2 mRNA levels in visceral white adipose tissue (visWAT) compared to subcutaneous white adipose tissue (scWAT)

• Substantially higher HAND2 expression in subcutaneous white adipose tissue than in brown adipose tissue (BAT)

• Inverse correlation between HAND2 expression in visWAT and BMI in humans

Neural expression:

• Essential for maintenance of noradrenergic phenotype in sympathetic neurons

• Detected in neuronal cell lines like Neuro-2a (mouse neuroblastoma) and SH-SY5Y (human neuroblastoma)

Disease-specific alterations:

• Lower HAND2 levels in obese or diabetic patients compared to lean individuals, especially in visceral adipose tissue

What methodological approaches are recommended for dual/multi-label detection of HAND2 with other developmental markers?

For co-localization studies with HAND2 and other developmental markers:

• Sequential immunostaining protocol:

  • Begin with the least sensitive antibody (typically HAND2)

  • Use species-distinct primary antibodies (e.g., goat anti-HAND2 and rabbit anti-TH)

  • For chromogenic detection, use different substrates (e.g., DAB for HAND2 and Vector Red for second marker)

  • For fluorescence, use spectrally distinct fluorophores with minimal overlap

• Marker selection for developmental contexts:

  • For cardiac development: Pair HAND2 with NKX2.5, GATA4, or TBX5

  • For sympathetic neuron development: Combine with TH, DBH, and SCG10

  • For adipocyte differentiation: Co-stain with PPARγ or C/EBPα

• Technical considerations:

  • Optimize antigen retrieval conditions for both markers

  • Consider tyramide signal amplification for low-abundance markers

  • Perform appropriate controls including single-labeled specimens

  • Include blocking steps to prevent cross-reactivity between detection systems

• Analysis approaches:

  • Quantify co-localization using software like ImageJ with Coloc2 plugin

  • Report Pearson's correlation coefficient or Manders' overlap coefficient

How can I troubleshoot weak or absent HAND2 signal in Western blot applications?

When encountering weak or absent HAND2 signal in Western blotting:

• Protein extraction optimization:

  • HAND2 is a nuclear transcription factor; ensure nuclear extraction protocols are adequate

  • Include protease inhibitors to prevent degradation

  • For embryonic tissues, pooling multiple samples may be necessary due to low abundance

• Loading and transfer parameters:

  • Increase protein loading (20-40 μg of total protein typically works for transcription factors)

  • Verify transfer efficiency with reversible staining (Ponceau S)

  • Use PVDF membranes which may better retain low molecular weight proteins like HAND2 (24-26 kDa)

• Antibody optimization:

  • Try concentration range around 0.1 μg/mL for R&D Systems antibody

  • Extend primary antibody incubation to overnight at 4°C

  • Consider alternative antibody clones if repeatedly unsuccessful

• Detection enhancement:

  • Use high-sensitivity ECL substrates

  • Consider immunoprecipitation before Western blotting for enrichment

  • For SH-SY5Y cells, immunoprecipitation protocols have been validated

• Verification approaches:

  • Run positive control samples (e.g., recombinant HAND2 protein)

  • Confirm HAND2 band at approximately 26 kDa (slightly higher than the predicted 24 kDa)

What are effective protocols for immunoprecipitation of HAND2 protein complexes?

For successful immunoprecipitation of HAND2 protein complexes:

• Validated protocol from literature:

  • Use 0.35 mg of whole cell lysate (e.g., from SH-SY5Y cells)

  • Apply Anti-HAND2 antibody at 1/30 dilution for immunoprecipitation

  • For Western blot detection of immunoprecipitated HAND2, use 1/500 dilution

  • Include appropriate controls (IgG isotype control)

• Co-immunoprecipitation considerations:

  • For detecting HAND2 interaction partners (e.g., E12), use gentler lysis conditions

  • Consider crosslinking approaches for transient interactions

  • For DNA-bound complexes, adapt protocols from published ChIP-Seq methods that used 300 hearts per biological replicate

• Buffer optimization:

  • Include 5% NFDM/TBST as blocking and dilution buffer

  • Test both low and high salt washing conditions depending on interaction strength

  • For nuclear factors, include appropriate nuclear extraction buffers

• Validation approaches:

  • Verify identified interactions through reciprocal co-immunoprecipitation

  • Confirm functionality through reporter assays or DNA binding assays

How can I adapt HAND2 detection protocols for different model organisms?

Adapting HAND2 detection across species requires specific modifications:

• Sequence homology considerations:

  • Human and mouse HAND2 proteins share high homology, enabling use of the same antibodies

  • For less-studied species, perform sequence alignment to predict epitope conservation

  • Consider using conserved region-targeting antibodies (e.g., C-terminal region antibodies)

• Species-specific protocol modifications:

  • Mouse/Rat: Standard protocols work well with antibodies like R&D Systems AF3876

  • Chick: For siRNA knockdown experiments in sympathetic neurons, use Amaxa Nucleofector device with Program G13 protocol and 3μg siRNA

  • Zebrafish: Select antibodies with verified zebrafish reactivity and adapt fixation protocols with lower paraformaldehyde concentrations

• Validation in non-traditional models:

  • For amphibian models, Biorbyt offers frog-reactive HAND2 antibodies

  • Use tissue-specific positive controls based on conserved expression patterns

  • Consider Western blot verification of antibody specificity before immunohistochemistry

• Developmental timing adjustments:

  • Adjust sampling timepoints based on species-specific developmental progression

  • For mouse embryos, E9.0-E14.5 represents key stages for HAND2 expression studies

  • For other species, select equivalent developmental stages based on cardiac and neural crest development

How can I design experiments to study HAND2's role in transcriptional regulation through ChIP-Seq approaches?

For investigating HAND2's genomic binding and transcriptional regulation:

• Experimental design considerations:

  • Use Hand2 3xF allele encoding HAND2 protein with 3xFLAG epitope tag for reliable immunoprecipitation

  • Collect sufficient starting material (~300 hearts per biological replicate for embryonic studies)

  • Include two or more biological replicates for statistical validity

  • Target appropriate developmental timepoints (E10.25-10.5 for cardiac studies)

• Analytical approaches:

  • Identify significantly enriched genomic regions using MACS software

  • Assign peaks to neighboring genes using GREAT analysis

  • Focus on conserved sequences that overlap peak summits

  • Analyze peak distribution relative to transcriptional start sites (most HAND2 binding sites are ≥10kb from TSS)

• Integration with gene expression data:

  • Combine ChIP-Seq with differential expression analysis from Hand2-deficient tissues

  • Identify direct transcriptional targets by correlating binding with expression changes

  • Analyze genes with binding sites in their Topologically Associating Domains (TADs)

• Key findings from literature:

  • HAND2 binding sites are predominantly distal to transcription start sites

  • TADs of differentially expressed genes contain significantly more HAND2-interacting regions (median ~5) than non-regulated genes (median ~1)

What approaches are recommended for investigating HAND2's role in adipogenesis and metabolic disorders?

Recent research has identified HAND2 as an obesity-linked adipogenic transcription factor, requiring specialized approaches:

• Tissue-specific expression analysis:

  • Compare HAND2 expression between visceral white adipose tissue (visWAT), subcutaneous white adipose tissue (scWAT), and brown adipose tissue (BAT)

  • Examine correlations with clinical parameters (BMI, body weight)

  • Include samples from diverse metabolic states (lean, obese, diabetic participants)

• Experimental design for metabolic studies:

  • Stratify human cohorts carefully (e.g., equal numbers of lean, obese and diabetic participants)

  • Consider depot-specific differences in expression and function

  • Correlate HAND2 expression with metabolic parameters

• Functional validation approaches:

  • Develop adipocyte-specific Hand2 knockout or overexpression models

  • Analyze differentiation capacity, lipid accumulation, and metabolic gene expression

  • Investigate interaction with established adipogenic regulators like PPARγ

• Translational considerations:

  • HAND2 expression in visWAT inversely correlates with BMI in humans

  • Expression is lower in obese or diabetic participants compared with lean participants

  • These patterns suggest potential diagnostic or therapeutic relevance

How can I design conditional knockout experiments to study stage-specific HAND2 functions?

For investigating stage-specific HAND2 functions through conditional approaches:

• Genetic strategies:

  • For embryonic studies, utilize Hand2-null alleles

  • For stage-specific deletion, use conditional Hand2-null allele with appropriate Cre recombinase drivers

  • For sympathetic neuron studies, DBH-Cre drivers effectively target differentiated neurons

• Experimental design considerations:

  • Select developmental timepoints based on research question (E9.0-E14.5 range for most developmental studies)

  • Include littermate controls for all analyses

  • Design genotyping protocols that distinguish conditional from constitutive alleles

• Phenotypic analysis approaches:

  • For neuron development, assess:

    • Cell proliferation and neuron numbers

    • Expression of noradrenergic markers (TH, DBH)

    • Pan-neuronal genes (TuJ1, HuC, SCG10) as controls

  • For cardiac development, evaluate:

    • Atrioventricular canal formation

    • Expression of HAND2 target genes

    • Topological organization changes

• Rescue experiment design:

  • For in vitro rescue, combine siRNA knockdown with expression plasmids:

    • Control: control siRNA + pCAGGS-eGFP

    • Overexpression: control siRNA + pCAGGS-eGFP + pCAGGS-z/mHand2

    • Knockdown: Hand2 siRNA + pCAGGS-eGFP

    • Rescue: Hand2 siRNA + pCAGGS-eGFP + pCAGGS-z/mHand2